抗肿瘤纳米药物临床转化研究进展  

Current status and prospect of cancer nanomedicine in clinical translation

作　　者：刘静[1] 唐浩 米鹏 魏于全[1] LIU Jing;TANG Hao;MI Peng;WEI Yuquan(State Key Laboratory of Biotherapy)

机构地区：[1]四川大学华西医院生物治疗国家重点实验室

出　　处：《科技导报》2018年第22期118-126,共9页Science & Technology Review

基　　金：国家重点研发计划项目(2017YFA0207900)

摘　　要：纳米药物作为一种新兴的药物制剂,显示出为癌症患者提供副作用更小和具有靶向效果的治疗前景。近年来,随着纳米生物技术的发展,纳米药物的研发和临床转化取得了巨大的进展。现有很多纳米药物已经进入临床试验,其中部分产品已获得批准,在临床上应用于肿瘤治疗,改善了治疗效果。但是,肿瘤的复杂性和异质性,也为纳米药物对肿瘤的治疗带来巨大的挑战。本文从纳米药物的临床转化角度出发,概述了癌症纳米药物的发展和现状,纳米药物在临床转化中进展及面临的挑战与机遇。Nanomedicine has emerged to be a promising platform for cancer treatment with reduced side effect and increased therapeutic effect.In recent decades,with the advances in nanobiotechnology,much progress has been achieved in the development and clinical translation of cancer nanomedicines.Until now,several types of nanomedicines have been approved for cancer treatment in clinical and more candidates are in clinical trial.However,it is still a challenge for nanomedicines to treat tumors due to the complexity and heterogeneity nature of tumors.Herein,we summarize the current status and progress of cancer nanomedicines in clinical translation as well as discuss the challenge and future perspective.

关 键 词：纳米药物 肿瘤 药物递送系统 靶向治疗 临床转化 

分 类 号：R979.1[医药卫生—药品]